Cytori Therapeutics Inc. (NASDAQ:CYTX) was down 3.2% during mid-day trading on Wednesday . The company traded as low as $2.11 and last traded at $2.14, with a volume of 99,238 shares changing hands. The stock had previously closed at $2.21.

A number of equities research analysts have recently issued reports on CYTX shares. Maxim Group reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Cytori Therapeutics in a research note on Wednesday, July 20th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Tuesday, July 12th. Finally, Roth Capital restated a “buy” rating and issued a $11.00 price objective on shares of Cytori Therapeutics in a report on Tuesday, June 28th.

The stock’s 50 day moving average price is $2.05 and its 200 day moving average price is $2.78. The company’s market cap is $44.67 million.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.04. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $2.50 million. During the same period in the previous year, the business posted ($0.06) earnings per share. Cytori Therapeutics’s revenue for the quarter was down 31.3% compared to the same quarter last year. On average, analysts forecast that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.